Prognostic Value of Serum 1,5-anhydroglucitol Levels in Patients with Acute Myocardial Infarction

TL;DR

This study shows that low levels of a blood sugar marker, 1,5-anhydroglucitol, can predict poor outcomes in heart attack patients.

Contribution

The study identifies 1,5-anhydroglucitol as a novel predictor of cardiovascular events in acute myocardial infarction patients.

Findings

Low 1,5-AG levels were significantly associated with major adverse cardiovascular events.

1,5-AG levels were not significantly linked to all-cause mortality in heart attack patients.

Abstract

Diabetes mellitus is a major risk element for
cardiovascular disease. In the present study we investigated whether
1,5-anhydroglucitol (1,5-AG), a new marker for glucose monitoring, can predict
patient outcome following acute myocardial infarction (AMI).

A
total of 270 AMI patients who underwent coronary angiography (CAG) at
Beijing Hospital from March 2017 to 2020 were enrolled in this prospective cohort
study. The serum 1,5-AG concentration and biochemical indicators were evaluated
prior to CAG. Cox regression analysis was used to investigate the relationship
between 1,5-AG levels and major adverse cardiovascular and cerebrovascular events
(MACCEs), and with all-cause mortality.

During the median
follow-up period of 44 months, 49 MACCEs occurred and 33 patients died. The
1,5-AG level was significantly lower in the MACCEs group than in the MACCEs-free
group (p = 0.001). Kaplan-Meier analysis also revealed that low 1,5-AG
levels were associated with MACCEs (p < 0.001) and with all-cause
mortality (p = 0.001). Multivariate analysis showed that low 1,5-AG
(≤8.8 μg/mL) was an independent predictor of MACCEs (hazard ratio (HR)
2.000, 95% confidence interval (CI): 1.047–3.821, p = 0.036). However, 1,5-AG was not a
significant predictor for all-cause mortality in AMI patients (p >
0.05).

Low 1,5-AG levels can predict MACCEs in AMI
patients, but not all-cause mortality.

NCT03072797.

Figures